New hope for fighting back against aggressive brain tumors
NCT ID NCT02586857
Summary
This study tested an experimental drug called acalabrutinib (ACP-196) in adults whose aggressive brain cancer (glioblastoma) had returned after one or two prior treatments. The goal was to see if the drug could shrink tumors and was safe for these patients. It was an early-stage trial involving 24 participants to gather initial evidence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Los Angeles, California, 90095-1769, United States
-
Research Site
Palo Alto, California, 94304, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Boston, Massachusetts, 2215, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Vancouver, Washington, 98684, United States
Conditions
Explore the condition pages connected to this study.